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Background: In patients with type 2 diabetes (T2DM) fixed-dose 
antihyperglycaemic combinations (FDCs) may provide complemen-
tary efficacy, reduce tablet burden, and improve compliance. The 
aim of this study was to assess the bioequivalence and tolerability 
of 2 strengths of dapagliflozin (DAPA)/metformin extended-release 
(MET-XR) FDCs versus their individual components (ICs) in healthy 
subjects.
Material and Methods: This open-label, randomised, 2-way crosso-
ver, 4-arm study was conducted in 141 healthy adult Brazilian sub-
jects. Two oral doses (5 mg DAPA/500 mg MET-XR and 10 mg 
DAPA/1000 mg MET-XR) were evaluated in fed and fasted states.
Results: Under fed and fasting conditions the 5 mg DAPA/500 mg 
MET-XR FDC was bioequivalent to its ICs (Table). The 10 mg 
DAPA/1000 mg MET-XR FDC was bioequivalent to its ICs only 
in fed patients. Cmax for metformin was not bioequivalent to its ICs 
(upper 95% CI outside 80%–125%) in fasted patients; this small 
increase was not considered clinically meaningful as metformin is 
recommended to be administered with food. The safety and toler-
ability of the FDCs were generally similar to their ICs; no serious 
adverse events were reported.
Conclusions: Both DAPA/MET-XR FDCs were bioequivalent to their 
ICs, except 10mg DAPA/1000mg MET-XR in fasted patients, sup-
porting their use in patients with T2DM.
Parameter
Geometric mean 
point estimate of 
FDC/IC (%)
CI (90%) for the 
point estimate
5 mg DAPA/500 mg MET-XR
Arm-1 (n = 34) 
asted
Dapagliflozin Cmax 104.7 (96.3; 113.7)
AUC0-inf 101.1 (98.0; 104.2)
Metformin Cmax 96.7 (87.1; 107.5)
AUC0-inf 101.7 (93.3; 110.8)
Arm-2 (n = 29) 
Fed
Dapagliflozin Cmax 96.6 (88.0; 106.0)
AUC0-inf 102.0 (98.9; 105.2)
Metformin Cmax 100.9 (95.1; 107.0)
AUC0-inf 104.6 (97.3; 112.4)
10 mg DAPA/1000 mg MET-XR
Arm-3 (n = 34) 
Fasted
Dapagliflozin Cmax 103.7 (96.2; 111.7)
AUC0-inf 102.7 (100.7; 104.8)
Metformin Cmax 118.3 (109.8; 127.5)
AUC0-inf 112.6 (104.8; 120.9)
Arm-4 (n = 32) 
Fed
Dapagliflozin Cmax 91.9 (80.9; 104.4)
AUC0-inf 99.1 (97.0; 101.3)
Metformin Cmax 107.1 (102.6; 111.8)
AUC0-inf 98.6 (93.2; 104.3)
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Introduction: Reliable methods to quantify skin lesions are critical 
for the evaluation of disease severity and assessment of therapeu-
tic response. In dermatological trials often two dimensional digi-
tal photography is utilized which has inherent disadvantages. It 
appears that high-resolution three-dimensional (3D) imaging may 
offer many advantages such as offline 3D visualization and auto-
matic picture segmentation resulting in an objective and detailed 
skin lesion characterization. At present this technique is not opti-
mally technical and analytical validated which is a pre-requisite for 
clinical application.
Material and Methods: In this study we investigated the perfor-
mance and clinical use of the 3D skin-imaging LifeViz™ system 
(Quantificare, Sophia Antipolis, France) in conjunction with the 
DermaPix Software. The validation of the LifeViz Micro was con-
ducted with four trained operators that captured a synthetic phantom 
object on three different skin backgrounds at four time points during 
a period of one week.
Results: Coefficient of variations for volume of the 3D system were 
1.0%, 2.6% and 1.4% for inter-operator, skin background and inter-
day variability, respectively. The overall precision of the system was 
2.7% for volume, 1.6% for diameter and 4.1% for height. In order 
to determine accuracy of the system, a ruler was photographed and 
a mean error of 0.3% (range 0.0-0.8%) was observed. Preliminary 
data on cutaneous lesions also show low inter-observer variability 
and accurate images.
Conclusions: This validation study demonstrates that this novel 
3D-imaging system is precise and objectively quantifies a phantom 
object representing a skin lesion. The results support clinical use of 
this technology enabling high-resolution computation. Also the accu-
racy results are promising, but needs to be extended with accuracy 
assessment of absolute measurements. The preliminary clinical data 
suggest that application of this non-invasive imaging technique is 
suitable to quantitatively measure characteristics of cutaneous lesions 
and may be a promising tool in clinical trials.
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Introduction: The elderly population has been growing significantly, 
leading to an increased prevalence of chronic diseases and conse-
quent taking medication. The complex therapies of elderly can lead 
to therapy non-adherence, increasing several health risks.
Aim: This study aimed to estimate the prevalence of therapy adher-
ence and associated factors.
Material and Methods: This cross-sectional study was based on a 
questionnaire, with MAT scale (measure of adherence to therapy) 
validated for the Portuguese population (Lima, 2001) based on 
the Morisky scale, applied to 52 elderly (≥ 65 years) from northern 
Portugal. To assess therapy adherence, those whose average adher-
ence levels were ≥ 5, were called adherent. It was used descriptive 
statistics. The level of association between categories of variables was 
studied through the adjusted residuals (AdR) and the relationship 
between adherence to the therapeutic and the number of medications 
taken per day was studied using the Mann-Whitney U test, with a sig-
nificance level of 5%. The study was approved by Ethics Committee.
Results: The sample consisted mainly of males elderly (61.5% vs. 
38.5%), aged between 67 and 98 years (mean 82.71), and while 48.1% 
was between 75–84 years old. The participants shows high therapy 
adherence (96.2%). The non-adherent elderly are related to self-med-
ication (AdR= 4.3), with the high level of cholesterol (AdR= 2.9) and 
chronic pain (AdR= 2.9). The non-adherent elderly seem tend to take 
more drugs per day, although not statistically significant (P = 0.063).
Conclusions: This study shows that a large prevalence of elderly 
adhered to the therapy prescribed. Self-medication, having high 
cholesterol and chronic pain and higher number of different drugs 
per day seem related to non-adherence.
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Introduction: Drug-drug interactions constitute a predictable and 
in many cases avoidable cause of adverse drug reactions and thera-
peutic failure. We conducted a register-based study to investigate the 
prevalence of prescribed combinations of interacting drugs in the 
whole Swedish population (Holm et al. Eur J Clin Pharmacol. 2014).
Material and Methods: A retrospective, cross-sectional register 
study was conducted, covering four months in 2010. Data from 
the Prescribed Drug Register on all dispensed drug prescriptions in 
Swedish pharmacies from January 1 to April 30 were linked to the 
drug-drug interaction database SFINX. The analysis focused on drug 
interactions classified in the database as clinically relevant that can be 
handled, e.g. by dose adjustments (C-interactions), and clinically rele-
vant interactions that should be avoided (D-interactions). Interactions 
were categorized according to clinical consequence and drug type and 
prevalences of interacting drug combinations were described. The 
study was approved by the Regional Ethics Committee.
Results: About half of the population were dispensed at least one 
drug prescription. Mean (SD) number of dispensed drugs was 3.8 
(3.4). About 2.5 million potentially interacting drug combinations 
were identified in the study population of 9.3 million people. Among 
detected interactions 38% were classified as C-interactions and 3.8% 
as D-interactions. About half of all C- and D-interactions were com-
binations of drugs with potential to cause therapeutic failure. The 15 
most prevalent combinations accounted for 80% of D-interactions. 
The 10 most prevalent individual drugs were involved in 94% of all 
D-interactions.
Conclusions: A limited number of drugs and a few specific drug 
combinations account for the majority of D-interactions, i.e. clini-
cally relevant interactions that should be avoided, in Sweden. About 
half of interacting drug combinations among C- and D-interactions 
potentially leads to treatment failure.
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Uracil catabolism is crucial for the pharmacokinetics of the chemo-
therapeutic 5-fluorouracil (5-FU) since 5-FU is degraded by the 
same pathway. Decreased activity of the first catabolizing enzyme, 
dihydropyrimidine dehydrogenase (DPD), is a major predictor of 
5-FU toxicity with known risk variants in the DPD gene (DPYD) 
accounting for ~30% of toxicities. However, not all toxicity cases 
can be explained by DPYD risk variants. To date, the phenotypic 
variability in the catabolism downstream of DPD by dihydro-
pyrimidinase (DHP) and β -ureidopropionase (bUP), potentially 
contributing to 5-FU toxicity, has not been investigated. Thus, we 
aimed to characterize the baseline phenotypic variability of endog-
enous metabolites and metabolic ratios of 5-FU catabolism enzymes 
and to correlate the phenotype with genetic variation in the DHP 
and bUP genes (DPYS and UPB1).
Material and Methods: Three variants in DPYS and UPB1 previ-
ously associated with 5-FU toxicity were genotyped in 320 healthy 
volunteers and their plasma uracil, dihydrouracil (UH2), β -ureidopro-
pionic acid (UPA), and β -alanine (BAL) concentrations were deter-
mined by LC-MS/MS.
Results and Conclusions: High inter-individual variability in all met-
abolic ratios was observed. Sex-dependent differences were detected 
at each enzymatic step in the uracil catabolism pathway, with lower 
metabolite levels (P ≤ 0.007) in women. Moreover, lower UPA/UH2 
ratios (P < 0.001) were observed in women, suggesting that reduced 
5-Fluoro-UH2 catabolism may contribute to higher fluoropyrimi-
dine toxicity rates observed in females. Furthermore, volunteers 
carrying DPYS variant c.265-58T> C had lower UH2 plasma levels 
(P = 0.033) and higher UPA/UH2 ratios (P = 0.036) and carriers 
of the UPB1 variant c.1-80C> G showed lower BAL plasma levels 
(P = 0.004). These initial results are in agreement with the previously 
observed reduced fluoropyrimidine toxicity in c.265-58C carriers 
and increased toxicity in carriers of c.1-80G, indicating a possible 
functional effect related to these variants.
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Introduction: The growing aging of population and increasing preva-
lence of chronic diseases require the simultaneous use of drugs, lead 
to the issue of polypharmacy and potentially interactions and inap-
propriate use.
Aim: To characterize polymedicated elderly and related factors, iden-
tify potentially interactions and inappropriate medication in elderly.
Material and Methods: This cross-sectional study was based on 
a questionnaire applied to 69 elderly (≥ 65 years) from northern 
Portugal. It was considered as polymedicated seniors taking ≥ 5 
drugs. Beers list and the Delafuente classification were used to evalu-
ate the therapeutic and possible interactions. It was used descriptive 
statistics and a model of binary regression, with a significance of 5%. 
The study was approved by Ethics Committee.
Results: The sample consisted mainly of males (53.6% vs. 46.4%), 
aged between 66 and 99 years (mean 82.01), while 65.2% have 
more than 80 years. However, most elderly are not polymedicated 
(58%), on average 4.61 different drugs are administered per day 
(maximum= 19), antihypertensives (36.2%) and antacids (30.04%) 
are the most prescribed. Hypertension and depression increase the 
risk of polymedication eightfold (P = 0.004) and fivefold (P = 0.011) 
respectively. Female gender seems increase the risk of polypharmacy 
threefold, although not statistically significant (P = 0.102), and 
regarding age, the older age group (> 85 years) seems reduces the 
risk of polypharmacy in 0.6 fold, but also not statistically significant. 
According with Delafuente classification, 1.4% of elderly has poten-
tially drug interactions (Omeprazole and Iron salts). According to 
the list of Beers, 5.8% of seniors take drugs that classified as having 
some indications (hydroxyzine, amitriptyline).
Conclusions: Regarding polypharmacy, 42% of elderly are poly-
medicated with an average of about 5 different drugs per day, anti-
hypertensives and antacids the most prescribed. Hypertension and 
depression are highly associated with polypharmacy. We identified 
